Patents by Inventor Divyakant Desai
Divyakant Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10973768Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.Type: GrantFiled: February 28, 2013Date of Patent: April 13, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
-
Publication number: 20170333353Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: March 6, 2017Publication date: November 23, 2017Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 9616028Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: May 7, 2015Date of Patent: April 11, 2017Assignees: AstraZeneca AB, AstraZeneca UK LimitedInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20150238421Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: May 7, 2015Publication date: August 27, 2015Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 9050258Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: August 13, 2013Date of Patent: June 9, 2015Assignee: AstraZeneca ABInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20150050335Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.Type: ApplicationFiled: February 28, 2013Publication date: February 19, 2015Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
-
Publication number: 20130330406Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: August 13, 2013Publication date: December 12, 2013Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb CompanyInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 8535715Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: November 12, 2010Date of Patent: September 17, 2013Assignees: Bristol-Myers Squibb Company, AstraZeneca UK LimitedInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20120282336Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: November 12, 2010Publication date: November 8, 2012Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20110217342Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: ApplicationFiled: May 16, 2011Publication date: September 8, 2011Inventors: Sanjeev Kothari, Divyakant Desai
-
Publication number: 20070275059Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: ApplicationFiled: November 2, 2004Publication date: November 29, 2007Inventors: Sanjeev Kothari, Divyakant Desai
-
Publication number: 20070141154Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.Type: ApplicationFiled: January 30, 2007Publication date: June 21, 2007Inventors: Danping Li, Li Phusanti, Divyakant Desai
-
Publication number: 20060099254Abstract: The present invention relates to a pharmaceutical delivery system comprising a gel-like structure that comprises at least one water-soluble polymer, such as, for example, povidone or hydroxypropyl cellulose, and at least one fatty acid, such as, for example, stearic acid or lauric acid. The invention further relates to a sustained release drug delivery composition comprising the gel-like structure and at least one drug trapped or dissolved therein, wherein said system is capable of releasing the drug in a dissolution medium at a controlled rate. The invention is also directed to a method for preparing the sustained release drug delivery composition.Type: ApplicationFiled: November 2, 2005Publication date: May 11, 2006Inventors: Divyakant Desai, Sanjeev Kothari, Laxmikant Sharma
-
Publication number: 20050266080Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: ApplicationFiled: May 25, 2005Publication date: December 1, 2005Inventors: Divyakant Desai, Bing Li
-
Publication number: 20050214373Abstract: A coated tablet formulation is provided which includes a medicament such as the PPAR ?/? dual agonist peliglitazar or muraglitazar. The coated tablet includes a tablet core containing one or more fillers, one or more binders, one or more disintegrants, and other conventional excipients, and a coating on the tablet core, which coating may include one or more layers, at least one layer of which is formed of medicament and one or more coating polymers, preferably a hydroxypropylmethyl cellulose based polymer. A method for forming the coated tablet via a spray-dried coating technique is also provided.Type: ApplicationFiled: March 21, 2005Publication date: September 29, 2005Inventors: Divyakant Desai, Danping Li
-
Publication number: 20030190334Abstract: Liquid pharmaceutical compositions are provided having a low dose of entecavir. In one embodiment of the present invention, the liquid entecavir composition is a ready-to-use composition that is formulated to be both stable and palatable. In a second embodiment of the present invention, the liquid entecavir composition is formulated from a powder composition at the time of use. The low dose entecavir compositions may also include at least one component selected from sweetener, preservative, flavoring agent, buffering agent, or combinations thereof. The liquid entecavir compositions may also be formulated in combination with other pharmaceutically active agents.Type: ApplicationFiled: April 4, 2003Publication date: October 9, 2003Inventors: Divyakant Desai, Danping Li
-
Patent number: 6627224Abstract: Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulations for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately administered for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.Type: GrantFiled: February 23, 2001Date of Patent: September 30, 2003Assignee: Bristol-Myers Squibb Co.Inventors: Richard J. Colonno, Omar L. Sprockel, Abizer Harianawala, Divyakant Desai, Michael G. Fakes
-
Publication number: 20020076437Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: ApplicationFiled: October 9, 2001Publication date: June 20, 2002Inventors: Sanjeev Kothari, Divyakant Desai
-
Publication number: 20010033864Abstract: Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulations for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately administered for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.Type: ApplicationFiled: February 23, 2001Publication date: October 25, 2001Inventors: Richard J. Colonno, Omar L. Sprockel, Abizer Harianawala, Divyakant Desai, Michael G. Fakes